Literature DB >> 1123855

Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro.

A J Treves, I R Cohen, M Feldman.   

Abstract

To learn whether tumor metastases can be prevented by the immune system, we developed a model for the treatment of mice with syngeneic lymphocytes sensitized against tumor cells in vitro. Mice were given subcutaneously tumor cells that spontaneously metastasized to the lungs. The tumors developing locally were surgically removed and the mice were inoculated with sensitized lymphocytes 1 day later. Prevention of death by lung metastases was the measure of immunotherapy. Only approximately equal to 30-40 percent of mice receiving control treatment survived, whereas approximately equal to 70 percent survived that received lymphocytes sensitized in vitro against the tumor cells. Hence sensitization of syngeneic lymphocytes against tumor cells in vitro and injection of the lymphocytes into the host after removal of a local tumor prevented the development of lethal metastases.

Entities:  

Mesh:

Year:  1975        PMID: 1123855

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

1.  Mitogenic stimulation of human tumor-infiltrating lymphocytes by secreted factor(s) from human tumor cell lines.

Authors:  B S Packard
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

Review 2.  Specific adoptive immunotherapy: experimental basis and future potential.

Authors:  P D Greenberg; M A Cheever; A Fefer
Journal:  Surv Immunol Res       Date:  1982

3.  Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.

Authors:  T J Eberlein; M Rosenstein; P Spiess; R Wesley; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

Review 4.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

5.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer; S Gillis
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

6.  Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors.

Authors:  M Laude; K L Russo; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

Review 7.  Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants.

Authors:  R S Kerbel; J W Dennis; A E Largarde; P Frost
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

8.  Liposome facilitated xenogeneic approach for studying human colon cancer immunity: carrier and adjuvant effect of liposomes.

Authors:  L Raphael; B H Tom
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

9.  Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract.

Authors:  N Kan; K Ohgaki; T Inamoto; H Kodama
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

10.  Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.

Authors:  M Rodolfo; C Salvi; C Bassi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.